Physician profile
Daniel Christopher Schubert
NPI 1780670364
$1,203.60
in general payments reported to CMS, 2019-2025
23 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $138 · 2021: $223 · 2022: $135 · 2023: $149 · 2024: $245 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $316.38 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $250.09 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $74.72 | 2024-2025 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $68.30 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $63.52 | 2022 | |
| Sage Therapeutics, LLC | $60.91 | 2024-2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $50.22 | 2020-2022 | |
| Lilly USA, LLC | $39.32 | 2019-2020 | |
| Amgen INC. | $35.70 | 2019-2020 | |
| Novo Nordisk INC | $26.43 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $25.00 | 2025 | Qelbree |
| Pacira Pharmaceuticals Incorporated | $24.47 | 2023 | Exparel |
| Myovant Sciences INC. | $21.27 | 2021 | |
| Coloplast Corp | $18.40 | 2024 | |
| Horizon Therapeutics Plc | $18.03 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2021 | |
| Eisai INC. | $14.45 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.42 | 2020 | |
| Genentech USA, INC. | $13.25 | 2019 | |
| Mayne Pharma Commercial LLC | $12.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.90 | 2019 | |
| Amarin Pharma, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.